MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players
As part of Protisvalor, the research transfer subsidiary of Aix-Marseille University, I have accompanied researchers from the University for nearly 4 years, first to identify European funding opportunities to meet their needs and then to help them develop proposals for submission to the European Commission. As an immunologist, I have participated in all stages of the innovation chain of Marseille Immunopôle, from research to industry and technology transfer. I have always followed R&D projects with particular interest on collaborative projects focused on immunology, involving both scientists, clinicians and industrials.
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players. MI will make us more visible and efficient. Together, we have the unique opportunity to make Marseille metropolis a global hub for fundamental and applied immunology and a capital for immunotherapy R&D. Being involved in this very ambitious project is a privilege and a real responsibility!#ecosystème
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Our aim is simple: to position ourselves upstream of the diagnosis and to propose innovative treatments to patients
AMU, IPC, CRCM
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the g9d2 T cells and a novel superfamily of immunomodulators, butyrophilins”
MI-mAbs allows researchers to validate the therapeutic potential of their discovery and permits industrials to focus their efforts on the most promising drug candidate